Kynam Capital Management, LP
PRINCETON, NJ
$1.8bn in 32 US stocks at the end of 30 June 2026. The top 10 are 72.7% of the money. It changed about 20.3% of the portfolio this quarter.
Value
$1.8bn
Stocks
32
Top 10 share
72.7%
Turnover
20.3%
What changed this quarter
New
Bought for the first time this quarter.
- Summit TherapeuticsSMMT1.0% of the fund
- InsmedINSM0.6% of the fund
- Parabilis MedicinesPBLS0.4% of the fund
- enGene TherapeuticsENGN<0.1% of the fund
- Traws PharmaTRAW<0.1% of the fund
Added
Bought more of a stock they already held.
- Viridian TherapeuticsVRDN6.6% of the fund+176%
- Travere TherapeuticsTVTX6.3% of the fund+27%
- UroGen PharmaURGN5.0% of the fund+8%
- Legend BiotechLEGN4.8% of the fund+90%
- CytomX TherapeuticsCTMX4.5% of the fund+45%
- Relay TherapeuticsRLAY3.4% of the fund+132%
- Immunocore HldgsIMCR2.4% of the fund+55%
- PharvarisPHVS1.3% of the fund+3%
- Prelude TherapeuticsPRLD0.7% of the fund+52%
- AmarinAMRN0.5% of the fund+13%
- AlectorALEC0.4% of the fund+90%
Cut
Sold some of their stake.
- Celldex TherapeuticsCLDX10.9% of the fund-9%
- Cogent BiosciencesCOGT7.8% of the fund-9%
- Vera TherapeuticsVERA6.9% of the fund-15%
- Beam TherapeuticsBEAM5.4% of the fund-23%
- Biocryst PharmaceuticalsBCRX1.4% of the fund-56%
- Candel TherapeuticsCADL<0.1% of the fund-52%
Sold out
Sold their entire stake.
- Kalvista Pharmaceuticals-100%
- Apellis Pharmaceuticals-100%
- Soleno Therapeutics-100%
- EvommuneEVMN-100%
- Engene Holdings-100%
- Design TherapeuticsDSGN-100%
- Wave Life SciencesWVE-100%
- Climb BioCLYM-100%
- BiohavenBHVN-100%
Holdings
- Legend BiotechLEGN
- Share
- 4.8%
- Value
- $87m
- Shares
- 3,001,205
+90%
- Immunocore HldgsIMCR
- Share
- 2.4%
- Value
- $44m
- Shares
- 1,375,000
+55%
- Burning Rock BiotechBNR
- Share
- 0.6%
- Value
- $11m
- Shares
- 1,238,563
Held
- AmarinAMRN
- Share
- 0.5%
- Value
- $8m
- Shares
- 532,982
+13%
- Parabilis MedicinesPBLS
- Share
- 0.4%
- Value
- $7m
- Shares
- 250,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Celldex TherapeuticsCLDX | 10.9% | $198m | 5,322,908 | -9% |
| Syndax PharmaceuticalsSNDX | 9.7% | $176m | 8,050,959 | Held |
| VaxcytePCVX | 9.4% | $170m | 2,922,335 | Held |
| Cogent BiosciencesCOGT | 7.8% | $142m | 3,667,097 | -9% |
| Vera TherapeuticsVERA | 6.9% | $124m | 2,890,059 | -15% |
| Viridian TherapeuticsVRDN | 6.6% | $119m | 6,453,877 | +176% |
| Travere TherapeuticsTVTX | 6.3% | $114m | 2,000,000 | +27% |
| Beam TherapeuticsBEAM | 5.4% | $97m | 2,840,792 | -23% |
| UroGen PharmaURGN | 5.0% | $90m | 2,434,207 | +8% |
| Legend BiotechLEGN | 4.8% | $87m | 3,001,205 | +90% |
| CytomX TherapeuticsCTMX | 4.5% | $81m | 21,703,093 | +45% |
| Relay TherapeuticsRLAY | 3.4% | $62m | 3,300,000 | +132% |
| Cullinan TherapeuticsCGEM | 3.1% | $57m | 3,114,132 | Held |
| MBX BiosciencesMBX | 2.9% | $52m | 934,799 | Held |
| Immunocore HldgsIMCR | 2.4% | $44m | 1,375,000 | +55% |
| Nurix TherapeuticsNRIX | 1.6% | $29m | 1,194,757 | Held |
| Sutro BiopharmaSTRO | 1.6% | $29m | 872,558 | Held |
| Biocryst PharmaceuticalsBCRX | 1.4% | $25m | 2,522,660 | -56% |
| PharvarisPHVS | 1.3% | $23m | 661,795 | +3% |
| Summit TherapeuticsSMMT | 1.0% | $17m | 1,200,000 | New |
| Prelude TherapeuticsPRLD | 0.7% | $13m | 2,415,087 | +52% |
| InsmedINSM | 0.6% | $11m | 100,000 | New |
| Burning Rock BiotechBNR | 0.6% | $11m | 1,238,563 | Held |
| GeronGERN | 0.5% | $9m | 6,836,318 | Held |
| AmarinAMRN | 0.5% | $8m | 532,982 | +13% |
| AlectorALEC | 0.4% | $8m | 3,808,494 | +90% |
| Parabilis MedicinesPBLS | 0.4% | $7m | 250,000 | New |
| Caribou BiosciencesCRBU | 0.2% | $4m | 2,503,302 | Held |
| ProQR TherapeuticsPRQR | 0.2% | $3m | 1,566,317 | Held |
| Candel TherapeuticsCADL | <0.1% | $996,432 | 96,741 | -52% |
| enGene TherapeuticsENGN | <0.1% | $792,089 | 457,855 | New |
| Traws PharmaTRAW | <0.1% | $71,175 | 84,400 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 94.8% since 30 June 2025.
Where the money is
Health care91.7%
Other8.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.